Leadership
Co-founder and Chairman of Westlake Pharmaceuticals
Dr. Yu is a world-renowned cell biologist. He is a recipient of the Chang Jiang Scholars Program Chair Professorship，and was selected for the Zhejiang Province Kunpeng Plan, and the New Cornerstone Investigator Program.
Dr. Yu received his bachelor’s degree in chemistry from Peking University and received his Ph.D. in chemistry from Harvard University. Dr. Yu began his independent research career in Department of Pharmacology at University of Texas Southwestern Medical Center and was promoted to Associate Professor with tenure and then to Professor. He was the holder of the Serena S. Simmons Distinguished Chair in Cancer Immunopharmacology. And he also served as the Howard Hughes Medical Institute (HHMI) investigator.
Dr. Yu was elected Fellow of the American Association for the Advancement of Science (AAAS) in 2012 and Board Member of Chinese Biological Investigator Society (CBIS) in 2018.
Co-founder and Director of Westlake Pharmaceuticals
Dr. Hu received his bachelor’s degree in pharmaceutical sciences and master’s degree in medicinal chemistry from Peking University. He then joined Tsinghua University and received his Ph.D. in biology.
In 2015, he joined Prof. Kevan Shokat’s lab in the University of California, San Francisco for postdoctoral training.
Dr. Hu was awarded the prestigious Damon Runyon Postdoctoral Fellowship in 2015.
Co-founder and Director of Westlake Pharmaceuticals
Dr. Huang is a leading figure in both Computer-Aided Drug Design(CADD) and Artificial Intelligence-Driven Drug Design (AIDD) in China, providing scientific consulting services to AI-driven pharmaceutical companies such as XtalPi and DP Technology, as well as top Internet companies such as ByteDance, Baidu and Tencent, and conducting related research in collaboration with these companies.
Dr. Huang received his bachelor’s degree and master’s degree in physics at Tsinghua University, and his Ph.D. in chemistry at University of Basel in Switzerland.
Dr. Huang did his postdoctoral training from 2012 to 2017 in the Computer-Aided Drug Design Center in University of Maryland School of Pharmacy. In 2015 he was awarded a research contract from National Institute of Health (NIH), and thus held a joint appointment in the Laboratory of Computational Biology at the National Heart, Lung, and Blood Institute, NIH.
